Member Info for OAPK20

OAPK20

Member since Apr 2009

Posts: 3,126

Price: 2.35

Bang On23 Apr 2026 15:06

If you are not interested fine.

If so 2.70 was rejected repeatedly, now you know why with today’s RNS.

Profits taking from 1.80 instead expansion and continuation.

Live Tape reads.

18/04/2026

Loss of 2.25 OR repeated rejection at 2.70

22/04/2026 vs 21/04/2026:

Bear case: Strengthened

Participation fully collapsed (no qualifying prints), confirming deterioration in engagement.

Bull case: Further weakened

Structure still holds above 2.25, but no evidence of demand or positioning into catalyst.

Probability: Shifted

Prior → Bull 38% / Bear 62%

Today → Bull 30% / Bear 70%

Key change:

Transition from weak-participation drift → zero-participation environment, with full signal misalignment.

Called it here 18/04/2026. Called JAN too.

Assays needed. Until then liquidity is everything. Are the samples at the lab and did they get there when they said? Lab are more helpful than the CEO here. Just like February.

The AIM Funding Gravity - Gravity Zone.

BASE CASE (55%): Breakdown continuing toward placing-level

resolution. Two consecutive fail breaches, weak close, bid ladder collapse, price at placing. The buy blocks are absorbing supply but at progressively lower prices — demand present but not controlling. Next session below 2.20 = confirmed breakdown.

COUNTER-CASE (45%): Capitulation absorption at placing floor. Four buy blocks zero sell blocks (confirmed buy-side flow), late buying into close, price holding placing level (2.25). If 2.25 holds and buy blocks continue, the placing floor is being defended and a base may form at the placing level.

CONFIRMATION TRIGGER (BASE — breakdown): close below 2.20 (updated fail) OR new low below 2.20 OR 2.20 bid (WINS) withdrawn.

CONFIRMATION TRIGGER (COUNTER — placing floor defence): close above 2.30 + 2.30 bid rebuilt + buy block continuation + no new low.

INVALIDATION TRIGGER: Close below 2.20

If Active Accumulation continues 1–3 sessions; overhang test at 3.00p sets up

@FirstDevRes

#FDR Reconnaissance at the Lander West #gold target 🎯 has refined drill hole locations ahead of the fully funded Phase I RC drilling programme.

Drilling also expected to commence shortly on neighbouring @ItechMinerals ground along the Stafford Gold Trend 👀

The estimated date of mobilisation / service commencement will be from 1 November 2026.

https://www.find-tender.service.gov.uk/Notice/033470-2026?origin=SearchResults&p=1

NHS England F02: Contract notice Notice identifier: 2026/S 000-033470 Procurement identifier (OCID): ocds-h6vhtk-060669 Published 13 April 2026, 5:32pm.

Closing date/time changed to: 12 June 2026, 12:00pm.

NHS Healthier You- Reference number C415740 - II.1.2) Main CPV code 85100000 - Health services

The Contracting Authority is procuring the NHS Healthier You Programme utilising the competitive provider selection process under the Health Care Services (Provider Selection Regime) Regulations 2023. This competitive provider selection process has multiple gateways as described in this notice.

The NHS Healthier You Programme procurement comprises of the following:

• NHS Healthier You Behavioural Support for Obesity Prescribing ("BSOP) Service"): Targeted support for individuals prescribed pharmacotherapy GLP-1 medications as approved in a Primary Care setting by NICE. Service Users provided with the BSOP Service are referred to as the "BSOP Cohort".

• NHS Healthier You Diabetes Prevention Programme ("DPP Service"): Support for individuals identified as at high risk of developing type 2 diabetes. Service Users provided with the DPP Service are referred to as the "DPP Cohort".

• NHS Healthier You Type 2 Diabetes Path to Remission ("T2DR Service"): Support for individuals diagnosed with type 2 diabetes within the last 6 years and living with overweight or obesity. Service Users provided with the T2DR Service are referred to as the "T2DR Cohort".

• NHS Healthier You Long Term Conditions Prevention Pilot ("LTCP Service"): Support for individuals diagnosed with hypertension. Service Users provided with the LTCP Service are referred to as the "LTCP Cohort".

The Contracting Authority has divided this opportunity into 26 ICB/ICB Clusters. ICB Clusters are groupings of ICBs. The complete list is set out in VI.3.

Bidders will need the capability and capacity to provide the full suite of services to an ICB/ICB Cluster, offering eligible participants a choice of group based in-person services or a digitally delivered, independently accessed service provided through a web browser or a mobile application. The Type 2 diabetes Path to Remission intervention will only be delivered on a one-to-one basis (delivered in-person or remotely).

Contracts will be awarded by Supplier. Bidders can be awarded a contract for more than one ICB/ICB Cluster. In such instances, one contract would be issued to the Supplier listing the ICB's/ICB Clusters awarded. This means a maximum of 26 contracts may be awarded in the event a different Supplier is awarded for each ICB/ICB Cluster.

Anticipated value across the ICB's/ICB Clusters is £386,000,000 excluding VAT. This is based on the initial term of 36 months. There will be an option to extend by up to 24 months, giving a maximum term of 60 months. The anticipated value of the 60 month term is £738,000,000 excluding VAT. VAT will be applied as appropriate. The estimated date of mobilisation / service commencement will be from

4.48:1 buy/sell block ratio, concentrated 907k cluster at 2.500p, best bid lifted to 2.40, Strong close position 71.4%

Next-session close above 2.50p would confirm overhang clearance sequence active.

Concentrated buy block cluster 13:16:40–13:18:24 (7 blocks within 1 minute 44 seconds totalling 907,089 shares, predominantly at 2.500p).

Buy block volume 1,119,589 vs sell block volume 250,000 = 4.48:1 buy-dominant

Tape reliability improved from 49.3% to 23.9%

INDIANAPOLIS, May 22, 2026 – Eli Lilly and Company (NYSE: LLY) announced a new analysis from the Phase 3 ATTAIN-1 and ATTAIN-2 trials showing that Foundayo (orforglipron), was associated with clinically significant body weight reductions in adults aged 65 and older with obesity or overweight, with or without type 2 diabetes. Foundayo is the only approved GLP-1 pill that can be taken any time of day without food or water restrictions. The post-hoc analysis was recently presented at ECO 2026 in Istanbul, Turkey.1

Key results: Weight loss in adults 65 and older

Foundayo at all doses tested was associated with statistically significant reductions in body weight compared with placebo at 72 weeks in adults ≥65, in both trials using the efficacy estimand (all p<0.001).2

ATTAIN-1 (participants with obesity or overweight and without T2D): At the highest dose, mean body weight reduction reached 13% in the observed data for adults 65 and older. Participants ≥65 years were associated with mean body weight reductions of -7.9% (5.5 mg), -11.3% (9 mg), and -13.0% (17.2 mg) vs. -1.6% with placebo. Comparable mean body weight reductions of -7.7% (5.5 mg), -9.2% (9 mg), and -12.4% (17.2 mg) were observed in adults <65 vs. -0.8% placebo.

ATTAIN-2 (participants with obesity or overweight and T2D): Participants ≥65 years were associated with mean body weight reductions of -7.5% (5.5 mg), -8.3% (9 mg), and -12.2% (17.2 mg) vs. -2.3% placebo. Comparable mean body weight reductions of -5.0% (5.5 mg), -7.6% (9 mg), and -9.9% (17.2 mg) were observed in adults <65 vs. -2.2% placebo.

Expert perspective: What the results could mean for patients

“Weight management in older adults requires careful consideration of both benefit and risk. These data are reassuring on both fronts —up to 13% weight loss was observed in patients 65 and older taking Foundayo, with a safety profile similar to what was observed in the broader trial populations,” said Rachel Batterham, M.D., senior vice president of medical innovation and external engagement, Lilly Cardiometabolic Health. “The fact that these results were achieved with a once-daily pill that patients can take at any time, without planning around meals or dealing with injections, matters in this age group.”

Key results: Safety profile across age groups

The safety profile of orforglipron was generally consistent across age groups and aligned with the overall ATTAIN-1 and ATTAIN-2 populations. Gastrointestinal adverse events, sometimes severe, including nausea, constipation, diarrhea, and vomiting were the most frequently reported events, consistent with the GLP-1 receptor agonist class.

Pooled serious adverse events (SAEs) were reported by 5.6%, 6.2%, and 5.4% of participants <65 years of age and 9.9%, 13.0%, and 11.6% of participants ≥65 years of age in the orforglipron 5.5 mg, 9 mg, and 17.2 mg groups, respectively, vs. 5.4% and 11.4% in the placebo group.

What is Foundayo (orforglipron)

Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake.5 Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, Foundayo is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About the ATTAIN trials and this analysis

ATTAIN-1 (NCT05869903) was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial that enrolled 3,127 adults (195 were ≥65) with obesity or overweight (BMI ≥27 kg/m²) without pre-existing T2D across multiple countries.3 ATTAIN-2 (NCT05872620) was a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial enrolling 1,613 adults (418 were ≥65) with obesity or overweight and T2D. In both trials, participants received one of three once-daily doses of orforglipron (5.5 mg, 9 mg, or 17.2 mg) or placebo, alongside healthy diet and physical activity guidance.4

This post hoc analysis examined efficacy and safety outcomes in subgroups of participants aged <65 and ≥65 years. Efficacy outcomes were analyzed separately for each study; safety data were pooled. The primary endpoint was percent change in body weight from baseline at Week 72.

Limitations

This is a post-hoc, exploratory analysis of data from the ATTAIN-1 and ATTAIN-2 trials. Results are not pre-specified and should be considered hypothesis-generating. The subgroups analyzed (≥65 and <65 years) reflect the distribution of participants enrolled in the trials; the number of participants ≥65 is smaller than the <65 subgroup, and formal comparisons between age groups were not pre-specified. These findings will need to be confirmed in dedicated prospective analyses.

Attention seeking 🔔ends

Outside the weight loss, patients using retatrutide did report various side-effects associated with the drug. Nausea was reported in 28.6% of participants receiving the 4mg dose, 38.4% on 9mg, and 42.4% on 12mg, compared with 14.8% in the placebo group. Other side-effects included diarrhea which affected 25.2%, 34.1%, and 32.0% of patients across the three dose groups, versus 13.5% on placebo. Constipation was reported by roughly one-quarter of treated patients compared with 10.9% of those receiving placebo.

Vomiting also increased with dose escalation, occurring in up to one in four patients on the highest dose, compared with 4.8% in the placebo group. Upper respiratory tract infections were reported in 14.2% of patients receiving 4mg of retatrutide, 12.2% on 9mg, and 13.1% on 12mg, compared with 11.6% in the placebo group.

“It was impressive to see that every dose of retatrutide resulted in clinically meaningful weight reduction for nearly all participants, and people with severe obesity on the highest dose lost on average 30% of their body weight over two years,” said Ania Jastreboff, a medicine and pediatrics professor at the Yale School of Medicine who led the study, in a statement accompanying the press release.

“Importantly, treatment with retatrutide not only resulted in robust weight reduction, but also in clear improvements in assessed cardio-metabolic health measures.”

With the recent rise in popularity of weight-loss drugs, emerging research suggests that GLP-1 receptor agonists may offer benefits beyond weight loss, including preventing anxiety and depression from worsening, as well as reducing sickness-related absences from work by nearly half.

Retatrutide also showed significant improvements from baseline in several cardiovascular risk factors including HDL cholesterol, triglycerides and systolic blood pressure, Eli Lilly said.

Https://www.theguardian.com/science/2026/may/21/weight-loss-shot-eli-lilly-glp-1

New weight-loss shot appears to outperform other obesity drugs on market

Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs

A new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced on Thursday.

The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lb (28.3%) over 80 weeks among participants receiving the 12mg dose, with 45.3% achieving at least 30% weight loss.

In Eli Lilly’s phase three trial, 2,339 adults who have obesity or are overweight, have at least one weight-related comorbidity, and have no diabetes were randomized to receive retatrutide in doses of 4mg, 9mg, 12mg, or a placebo. Over 80 weeks, participants receiving the highest doses achieved substantial weight loss, the company said.

Patients taking 9mg and 12mg of retatrutide lost an average of 64.4lb (25.9%) and 70.3lb (28.3%), respectively. Meanwhile, patients on the 4mg dose lost 47.2lb (19.0%) despite only a single dose-escalation step.

“This is the largest weight loss I’ve ever seen in any medication trial,” Dr Susan Spratt, an endocrinologist and the senior medical director for the Population Health Management Office at Duke Health in North Carolina told NBC News. “This is huge.”

The company also reported that 65.3% of participants on the 12mg regimen reduced their BMI below 30 – the clinical cutoff for obesity – including 37.5% of individuals who began the trial with a BMI of 40 or higher.

Based on Eli Lilly’s trial, weight loss with retatrutide appears to exceed what has been typically possible with other weight-loss medications, including Eli Lilly’s own Zepbound and Novo Nordisk’s Wegovy. On Zepbound, users can expect to lose an average of 15% to 20% of starting body weight over 72 weeks. On Wegovy, users can expect to lose an average of 14% to 19% of starting body weight gradually over 64 to 72 weeks.

While some weight-loss drugs, like Wegovy, now also come in a pill form, retatrutide and Zepbound are injected once a week with the dose increasing incrementally over time.

Retatrutide is a GLP-1, like Wegovy and Zepbound, and a GIP (glucose-dependent insulinotropic polypeptide), like Zepbound, but it also includes a hormone that none of the other weight loss drugs on the market have: glucagon, a hormone produced by the pancreas that raises blood sugar levels to prevent them from dropping too low. The three hormones working together help with your metabolism, controlling appetite and maintaining energy.

Https://www.baystreet.ca/stockstowatch/23349/Lilly-Weight-Loss-Drug-Clears-Hurdle

Lilly Weight Loss Drug Clears Hurdle

Eli Lilly (NYSE:LLY) on Thursday said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses.

News this morning says the results bring Lilly one step closer to filing for approval of the weekly injection, called retatrutide, which works differently from existing shots and pills from both Lilly and Novo Nordisk (NYSE:NVO). It also appears to be more effective than those options.

The highest dose of retatrutide helped patients lose 28.3% of their weight — or 70.3 pounds — on average over 80 weeks, compared with 2.2% with placebo, when evaluating only patients who stayed on the drug.

Roughly 45% of the 2,500 patients in the Phase 3 trial achieved 30% or more weight loss, Lilly said.

The highest dose also helped patients with a body mass index of 35 or above who participated in an extension of the study lose 30.3% of their weight on average over 104 weeks. That BMI threshold puts people at higher risk of cardiovascular complications or diabetes.

While the drug appeared to show higher rates of certain gastrointestinal side effects, such as nausea and diarrhea, especially at the highest dose, they were generally consistent with a previous Phase 3 trial of retatrutide in patients with obesity and a type of knee arthritis pain. Some analysts previously said those side effects highlight the speed and strength of the drug’s weight loss.

LLY shares began Friday ahead $15.96, or 1.5%, to $1,057.61.

Chunk hoovered

Prove up and sell better option

Five concurrent workstreams, and 2 sets of results soon.

•Artemisa North assay results. Samples already at lab (ALS Santiago).

•AMT survey results. 2-week survey, 4-6 week results.

•Artemisa North RC drilling (in progress)

•Artemisa South + Victoria (pending Artemisa N completion)

•AMT survey at La Colorada (commencing)

•Cerro Negro / Viuda mapping (ongoing)

•Mostaza metallurgical studies (underway)

Typical AIM assay turnaround: 4-8 weeks from sample delivery

Doctors are already calling for the NHS eligibility to be relaxed for weight loss patients. Once approved and eligibility is reviewed reckon the initial patient uptake will be rapid as they switch from injections. Just a case of how much and how quickly MPAL can capture market share. At these prices revenues could be juicy.

“UK Pricing and NHS Eligibility (2026 Update)

Pricing for the Wegovy pill in the UK has not yet been confirmed, but US pricing can provide a rough estimate.

Private Prescription Costs

At launch in the US, prices for the pill start at roughly $149 (approx. £115) to $299 (approx. £230) per month. The pill will likely be priced similarly in the UK. For context, Wegovy injections from UK Meds range from £110 to £220, depending on strength.

NHS Availability

NHS availability will likely lag behind the private market by 6 to 9 months.

After the MHRA approves the drug, NICE must conduct an appraisal to determine whether the pill is cost-effective for the NHS. If approved, it would likely be reserved for patients with a high body mass index (BMI), usually over 35, or over 30 with a weight-related health condition such as hypertension or high cholesterol.”

5p founder warrants

Rolly don’t discount forward selling future funding on news spike. Cash burn up Runway shortened